longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

BioKangtai

300601

11.770.86% ( +0.10 )
Delay Closed: Sep 17, 15:00:00
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI
  • ZAWYA-SNG: Egypt advances local production of pneumococcal vaccine through VACSERA partnership

    Zawya·Jan 20 at 05:18 AM
    300601+0.86%
  • BioKangtai: Quadrivalent influenza virus split vaccine (for the population aged 6-35 months) has initiated Phase I clinical trials

    Zhitong·Nov 3, 2025 at 11:14 AM
    300601+0.86%
  • BioKangtai released its performance for the first three quarters, with a net profit attributable to the parent company of 49.1577 million yuan, a decrease of 86%

    Zhitong·Oct 27, 2025 at 09:38 AM
    300601+0.86%
  • BioKangtai's net profit for the third quarter is 11.6 million yuan, and the net profit for nine months is 49.2 million yuan

    Zhitong·Oct 27, 2025 at 08:09 AM
    300601+0.86%
  • BioKangtai and AstraZeneca sign a license termination agreement

    Zhitong·Sep 30, 2025 at 08:12 AM
    300601+0.86%
  • BioKangtai: Application for marketing authorization of trivalent influenza virus split vaccine accepted

    Zhitong·Sep 24, 2025 at 10:06 AM
    300601+0.86%
  • BioKangtai: Sabin strain inactivated poliovirus vaccine (Vero cells) has obtained a drug registration certificate

    Zhitong·Sep 15, 2025 at 10:37 AM
    300601+0.86%
  • A-share innovative drug concept stocks fluctuated upward, EASTON BIOPHARMACEUTICALS and BioKangtai rose over 10%, Thalys, Staidson BioPharm, ALK, and ZHIFEI-BIOL followed suit

    Zhitong·Aug 25, 2025 at 01:41 AM
    300122+0.16%688513+0.89%
  • BioKangtai released its performance for the first half of the year, with a net profit attributable to the parent company of 37.5327 million yuan, a decrease of 77.30%

    Zhitong·Aug 21, 2025 at 12:31 PM
    300601+0.86%
  • BioKangtai: Trivalent influenza virus split vaccine approved for clinical trials

    Zhitong·Aug 18, 2025 at 08:04 AM
    300601+0.86%
  • BioKangtai: Yuan Liping reduced her holdings by 0.99%

    Zhitong·Aug 6, 2025 at 09:48 AM
    300601+0.86%
  • The biopharmaceutical sector is rising, with ZHIFEI-BIOL and WALVAX both up over 10%

    Zhitong·Jul 24, 2025 at 05:16 AM
    300122+0.16%300142+0.77%
  • BioKangtai shareholder Yuan Liping plans to reduce her holdings by no more than 1%

    Zhitong·Jul 1, 2025 at 10:24 PM
    300601+0.86%
  • BioKangtai: Adsorbed acellular DTP (component) combined vaccine initiates Phase III clinical trial

    Zhitong·May 30, 2025 at 08:14 AM
    300601+0.86%